Home > Oncology > Lenvatinib-pembrolizumab combo promising in advanced kidney cancer

Lenvatinib-pembrolizumab combo promising in advanced kidney cancer


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
The Lancet Oncology
Reuters Health - 05/07/2021 - The combination of the multikinase inhibitor lenvatinib and the anti-PD-1 antibody pembrolizumab has "encouraging" antitumor activity and a manageable side effect profile and might be an option following immune-checkpoint inhibitor (ICI) therapy in patients with metastatic renal-cell carcinoma (RCC), researchers report. Despite advances in the first-line treatment of metastatic RCC, there is "an unmet need" for options to address disease progression during or after treatment ICI therapy, Dr. Chung-Han Lee of Memorial Sloan Kettering Cancer Center, in New York City, and colleagues writes in The Lancet Oncology. Pembrolizumab and lenvatinib are active as monotherapies in RCC. The phase-1b/2 Study 111/KEYNOTE-146 trialists tested the combination in 145 patients with metastatic RCC. Two patients with non-clear-cell RCC were excluded from the efficacy analysis but included in the safety analysis. The efficacy population included 22 tr...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on